Active Ingredient(s): Sofosbuvir + Velpatasvir + Voxilaprevir
FDA Approved: * July 18, 2017
Category: Hepatitis

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Vosevi Overview

Voxilaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor (by Gilead) that is used in combination with sofosbuvir and velpatasvir.[2] The combination has the trade name Vosevi and received a positive opinion from the European Committee for Medicinal Products for Human Use in June 2017.[3] On 18 July 2017, Vosevi was approved by the US Food and Drug Administration.[4] References .mw-parser-output .reflist{fon...

Read more Vosevi Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Voxilaprevir

Recent Vosevi Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Sofosbuvir + Velpatasvir + Voxilaprevir
  • Tablet: 400mg + 100mg + 100mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Vosevi: (1 result)

Sorted by National Drug Code
  • 61958-2401 Vosevi Oral Tablet, Film Coated by Gilead Sciences, Inc.

Drugs with one or more similar ingredients: (7 results)